Are you curious about the new treatments for pain that may be coming soon to a city near you? Just follow the money:
Attendance is by invitation only. There’s no trade show floor. And, good luck tracking down information on speakers and schedules if you’re not invited — a public website for the event doesn’t even exist. Safe to say, this is not your typical conference or trade show.
The J.P. Morgan Healthcare Conference, to be held January 12-15, 2015, continues to be one of the life science industry’s largest and most frenzied conferences of the year. It reliably draws thousands of investors and executives across the healthcare sector to the Westin St. Francis Hotel in San Francisco as hundreds of companies present their latest innovations and dreams in an attempt to pique the interest of venture capitalists and potential partners…
ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain…
DUBLIN, Dec. 14, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that VIBERZI™ (eluxadoline), the company’s first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), is now available by prescription in the U.S.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro’s proprietary HF10 therapy…
Nektar Therapeutics has a robust R&D pipeline in pain, oncology, hemophilia and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development…
Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
NKTR-181 is a novel mu-opioid analgesic investigational drug candidate created using Nektar’s small molecule polymer conjugate technology. In preclinical studies, NKTR-181 exhibits a reduced rate of entry into the central nervous system (CNS) providing effective pain relief with fewer CNS-related side effects, such as euphoria, sedation and respiratory depression. The unique molecular design of the polymer conjugate also prevents conversion of NKTR-181 into free opioid or an abusable form of an opioid. As a result, NKTR-181 has the potential to be a highly effective analgesic with a favorable safety profile and reduced potential for abuse, misuse and diversion.
January 7, 2016 at 1:52 pm
Antagonistic to the pleasure receptors? So no pain, but you can’t get rewards even for exercise, intimate relations or a job well done? Sounds more like torture. Not buying it.